Answers are grounded in this paper and cite their sources.
Damoctocog alfa pegol (BAY 94-9027, Jivi®) is an extended half-life recombinant factor (F)VIII replacement, indicated for the treatment of haemophilia A in patients aged ≥12 years. Following introduction of damoctocog alfa pegol in Canada in 2020, there have been no reports on routine clinical effectiveness and satisfaction, when switching from a previous FVIII product in Canada.
No takes yet. Share an insight, caveat, or question.
Matino et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: